Compare Regeneron Pharmaceuticals Inc (REGN) vs First Trust Cloud Computing ETF (SKYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs First Trust Cloud Computing ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.40B), while First Trust Cloud Computing ETF trades at $169.97 (market cap $3.46B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 22.1× First Trust Cloud Computing ETF's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while First Trust Cloud Computing ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and First Trust Cloud Computing ETF for 84 Days on average.
| REGN | SKYY | |
|---|---|---|
Market Cap | $76.40B | $3.46B |
Volume | 626,381 | 180,124 |
Sector | Health | — |
52-Week High | $852.03 | $171.01 |
52-Week Low | $557.73 | $104.16 |
Typical Hold Time | 107 Days | 84 Days |
Enterprise Value | $71.12B | — |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
SKYY, the First Trust Cloud Computing ETF, trades at $170.78, near its 52-week high, with a slight daily decline of 0.13%. Technical indicators show a bullish trend from moving averages, while oscillators are neutral. Recent news highlights the ETF reaching new highs, driven by AI and cloud computing demand, with institutional adjustments in holdings. Financial ratios are not applicable as this is an ETF tracking a basket of cloud computing stocks.
The outlook for SKYY is positive, supported by secular trends in AI adoption and cloud infrastructure spending. Risks include market volatility and sector concentration, but the ETF offers diversified exposure without heavy reliance on mega-cap tech. Analyst sentiment is generally favorable, focusing on long-term growth opportunities in the cloud computing sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →
